The OmniPod System was also found to be safe, as there were no significant differences in episodes of diabetic ketoacidosis (DKA) or hypoglycemia requiring assistance among patients during the one-year OmniPod System use compared to the year prior to starting therapy. The overall acceptance rate for the OmniPod System in the study was 92.2%.

The study also reviewed 12 patients who switched to the OmniPod System from a conventional insulin pump and showed a reduction in average one-year A1C values by 0.2%. Researchers noted that although this difference was not statistically significant, the results were encouraging and the lack of statistical significance may be attributable to the small sample size of this study. A larger study to evaluate the A1C improvements in this patient population is recommended.